Neurological Disease  /  Economic Value

The prevalence of diseases like Alzheimer's and Parkinson's are skyrocketing as our population ages and they threaten to bankrupt our economy if better treatments and cures aren't found.  5.4 million Americans are currently diagnosed with Alzheimer’s disease. This number will triple to 16 million by the year 2050. Parkinson’s disease affects 1 million Americans, with at least 60,000 new cases occurring each year.

15 Matching Facts

Search matching Facts:
No results to display
    • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…  
    • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
    • An Alzheimer’s disease research study showed that billions of dollars could be saved if physicians could intervene before someone becomes symptomatic. This positive net savings occurred with both drug treatment…  
    • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
    • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
    • According to the Pharmaceutical Research and Manufacturers of America, every $1 spent on Alzheimer’s research would save Medicare $10 by 2015 and $25 by 2025.  
    • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.  
    • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
    • Combining gains in health-related knowledge of Alzheimer’s disease and its application for both genders, reductions in mortality between 1970 and 2000 yielded additional life-years with an end of century value…  
    • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.  
    • In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2…  
    • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…  
    • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
    • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
    • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.